Skip to content
My WebMD Sign In, Sign Up

Multiple Sclerosis Health Center

Font Size

Leukemia Drug Is Highly Effective MS Treatment

Alemtuzumab Lessens Relapses, Improves Disability

1 in 3 Users Develop Autoimmune Disease continued...

He says both conditions, while potentially serious, can be easily managed if patients are followed closely.

“Close monitoring is critical because these side effects tend to appear a year or two after treatment, when MS symptoms are often under control and patients want to get on with their lives,” he says.

National MS Society Chief Research Officer Tim Coetzee, PhD, says he does not see this as a big deterrent, since many of the newer drugs for multiple sclerosis also require close monitoring.

“Given the choice between having a treatment that requires aggressive monitoring and not having that treatment at all, I believe that most patients will take the treatment any day of the week,” he says.

Drug’s Cost as MS Treatment in Question

The drug maker Genzyme plans to market alemtuzumab as an MS treatment in the U.S. and Europe, pending approval by government regulators. The drug will not be available to MS patients during the approval process.

In an editorial published with the two studies, editors of the journal Lancet express concerns that the drug will be too expensive for patients and health systems when it is reintroduced as an MS treatment.

“Finding promising treatments such as alemtuzumab is important,” they write. “But so is keeping alemtuzumab accessible and affordable if its early success in these trials proves to be of enduring value.”

1|2

Today on WebMD

brain and teriflunomide molecule
ARTICLE
neural fiber
ARTICLE
 
white blood cells
VIDEO
linguini with asparagus and mushrooms
ARTICLE
 
brain scan
ARTICLE
worried woman
ARTICLE
 
person writin in a notebook
ARTICLE
couple embracing
ARTICLE
 
man with cane
SLIDESHOW
skull and neck xray
ARTICLE
 
Stressed man
ARTICLE
doctor feeling patients neck
ASSESSMENT